CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has established a new standard in accuracy for next generation sequencing. By adding an Exact Call Chemistry (ECC) proprietary probe to its market leading ligation chemistry, the company has demonstrated greater than 99.99% average single-read accuracy. This high-accuracy data is essential for the detection of minor variants in heterogeneous samples, a critical area of importance in cancer research. Further, the data is output in standard basepair format, allowing easier interface with third party tertiary data analysis tools.
